Repurpose.AI, LEO Pharma A/S Join Forces to Discover and Validate Drugs to Treat Inflammatory and Dermatology Indications

Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications. The research collaboration will leverage Repurpose.AI's ActivPred AI Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases. Previously, the company has successfully utilized the platform to discover REP-001, REP-002 and REP-003 – three Phase II/III ready small molecule assets for the treatment of Gastric, Neurological and Weight disorders, respectively. LEO Pharma A/S will share inflammatory and dermatology targets they consider to be of interest and will evaluate compounds discovered by Repurpose.AI in disease assays for potential therapeutic use in inflammatory skin diseases. LEO Pharma is a 111-year-old, foundation-owned global pharmaceutical company with over 6,000 employees and 2019 revenues in excess of EUR 1.4B. LEO Pharma has a well-established product portfolio focusing on dermatology and skin inflammation diseases that provides help to 92 million people globally. LEO Pharma is constantly innovating, exploring new opportunities and ways of working with external research partners. To achieve this, LEO Pharma has established the Open Innovation platform, a collaborative space where unique research tools are made available to external partners to enable the discovery and validation of sector changing therapeutics for patients suffering from inflammatory and dermatology indications.